As ironic as it may sound, our body’s protective mechanism can often end up causing discomfort. Take allergies, for instance, specifically allergic conjunctivitis (AC). It’s your body’s reaction to allergens like pollen, pet dander or dust mites but it can really put a damper on your daily life. With symptoms such as itchiness, redness, and increased tear production, these allergies have a significant impact on daily life for 30-40% of us.
Allergies typically involve an overzealous response from certain immune cells, and in this case, the perpetrator is the T helper 2 (Th2) cells. These guys drive allergic reactions by producing inflammatory substances. In simple terms, they kind of “overreact” when your eye comes in contact with allergens, thereby causing the troublesome symptoms.
Current available treatments only offer temporary relief, often accompanied by systemic side effects and drug resistance. We need new, effective solutions and that’s where the superheroes of the medical field – Mesenchymal Stem Cells (MSCs) – step in.
Mesenchymal Stem Cells: The Allergy Avengers
Research tells us these MSCs are pretty fantastic at managing allergic disorders. But, how they do it exactly, especially in the battleground of allergic conjunctivitis, was still a mystery. Until now.
A recent study sought to uncover just this. The researchers used the umbilical cord-derived variant of these cells (hUCMSCs), in a mouse model of conjunctival allergy. They experimented with injecting these cells subconjunctively (under the conjunctiva, the clear tissue covering the front of your eye) and measured the results.
The Results: A Win for Stem Cells
So, what happened? Good news – the hUCMSC injections led to less scratching and lower inflammation. Compared to other delivery methods, subconjunctival administration was found to be more effective. These cells showed their magic by reducing the number of activated mast cells, a type of immune cell implicated in allergic reactions, and other inflammatory cells in the eye.
The stem cells didn’t stop there. They also decreased the number of Th2 cells involved in this over-the-top immune response. They accomplished this by blocking the transformation of naive T cells, the potential Th2 cells, into actual Th2 cells.
Further investigations revealed that these stem cells were secreting something called CRISPLD2 to control the development of Th2 cells – a first-of-its-kind finding! In addition, they were found to promote the development of regulatory T cells, which are cells involved in curbing inflammation and allergic reactions.
Understanding the Game-Changer: Implications
This fantastic research has filled a significant gap in our understanding of how MSCs can help in allergic conjunctivitis. By regulating T cells’ response, these cells help control allergic reactions. The discovery of the molecular path via which hUCMSCs achieve this could transform how we approach this and other T-cell mediated diseases.
In essence, stem cell therapy could be a potential treatment option for allergies. It brings promise of a life where a dust mite, a pet, or a pollen grain, won’t send you reaching desperately for the eye drops. No more temporary relief, but a long-term solution. And isn’t that what we all dream of – lasting freedom from allergies?